Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB has announced an increase in its number of shares and votes by 1,004,100 due to the conversion of warrants in August 2025. This conversion has generated SEK 17.7 million for the company, potentially strengthening its financial position and supporting its ongoing efforts in the biotechnology sector.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company specializing in resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory effects in autoimmune and inflammatory diseases, aiming to help patients achieve immune balance.
Average Trading Volume: 172,427
Technical Sentiment Signal: Sell
Current Market Cap: SEK946.1M
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.